Tonix Pharmaceuticals (TNXP) Newsfilter·2025-03-13 11:00Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully-integrated biopharmaceutical company focused on pain management therapies and vaccines for public health challenges [4] - The company has a development portfolio primarily targeting central nervous system (CNS) disorders [4] Product Development - The company is advancing TNX-102 SL, a product candidate for fibromyalgia management, with a PDUFA goal date set for August 15, 2025, which could mark the first new treatment option for fibromyalgia patients in 15 years [2][4] - TNX-102 SL has received Fast Track designation from the FDA and is also being developed for acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina [4] - Other notable products in development include TNX-1300 for cocaine intoxication, which has FDA Breakthrough Therapy designation, and TNX-1500 for organ transplant rejection and autoimmune diseases [4] Financial and Strategic Partnerships - Tonix has secured a contract with the U.S. Department of Defense's Defense Threat Reduction Agency for up to $34 million over five years to develop TNX-4200, a broad-spectrum antiviral agent [4]